First Time Loading...

Taro Pharmaceutical Industries Ltd
NYSE:TARO

Watchlist Manager
Taro Pharmaceutical Industries Ltd Logo
Taro Pharmaceutical Industries Ltd
NYSE:TARO
Watchlist
Price: 42.26 USD 0.28%
Updated: Mar 28, 2024

Intrinsic Value

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. [ Read More ]

The intrinsic value of one TARO stock under the Base Case scenario is 28.2 USD. Compared to the current market price of 42.26 USD, Taro Pharmaceutical Industries Ltd is Overvalued by 33%.

Key Points:
TARO Intrinsic Value
Base Case
28.2 USD
Overvaluation 33%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Taro Pharmaceutical Industries Ltd

Backtest TARO Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TARO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Taro Pharmaceutical Industries Ltd

Current Assets 1.3B
Cash & Short-Term Investments 902.2m
Receivables 230.4m
Other Current Assets 214.8m
Non-Current Assets 815.8m
Long-Term Investments 403.5m
PP&E 218.4m
Intangibles 17.2m
Other Non-Current Assets 176.6m
Current Liabilities 374.1m
Accounts Payable 51.2m
Other Current Liabilities 322.9m
Non-Current Liabilities 10m
Other Non-Current Liabilities 10m
Efficiency

Earnings Waterfall
Taro Pharmaceutical Industries Ltd

Revenue
610.8m USD
Cost of Revenue
-317.5m USD
Gross Profit
293.3m USD
Operating Expenses
-271.3m USD
Operating Income
22m USD
Other Expenses
23.6m USD
Net Income
45.6m USD

Free Cash Flow Analysis
Taro Pharmaceutical Industries Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

TARO Profitability Score
Profitability Due Diligence

Taro Pharmaceutical Industries Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Positive Operating Income
Positive 1-Year Revenue Growth
43/100
Profitability
Score

Taro Pharmaceutical Industries Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

TARO Solvency Score
Solvency Due Diligence

Taro Pharmaceutical Industries Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Average Altman Z-Score
71/100
Solvency
Score

Taro Pharmaceutical Industries Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TARO Price Targets Summary
Taro Pharmaceutical Industries Ltd

Wall Street analysts forecast TARO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TARO is 43.86 USD with a low forecast of 43.43 USD and a high forecast of 45.15 USD.

Lowest
Price Target
43.43 USD
3% Upside
Average
Price Target
43.86 USD
4% Upside
Highest
Price Target
45.15 USD
7% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

TARO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

TARO Price
Taro Pharmaceutical Industries Ltd

1M 1M
+1%
6M 6M
+12%
1Y 1Y
+84%
3Y 3Y
-43%
5Y 5Y
-60%
10Y 10Y
-56%
Annual Price Range
42.26
52w Low
23
52w High
43.33
Price Metrics
Average Annual Return -26.9%
Standard Deviation of Annual Returns 11.82%
Max Drawdown -79%
Shares Statistics
Market Capitalization 1.6B USD
Shares Outstanding 37 580 000
Percentage of Shares Shorted 0.73%

TARO Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Taro Pharmaceutical Industries Ltd Logo
Taro Pharmaceutical Industries Ltd

Country

Israel

Industry

Pharmaceuticals

Market Cap

1.6B USD

Dividend Yield

0%

Description

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. The firm operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The firm markets over 200 pharmaceutical products in over 25 countries. The firm's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The firm's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Contact

Haifa
14 Hakitor Street, PO Box 10347
+97248475700.0
http://www.taro.com

IPO

1961-01-01

Employees

1 417

Officers

CEO & Director
Mr. Uday V. Baldota
VP, CFO & Chief Accounting Officer
Mr. William J. Coote
VP & Head of Operations
Mr. Itamar Karsenti
VP and Head of R&D
Mr. Avi Avramoff
Vice President of Technical Services
Mr. Itzik Baruch
Vice President of Scientific and Technical Compliance Manager
Dr. Roman Kaplan
Show More
VP, General Counsel & Secretary
Mr. Erik Zwicker J.D.
Vice President of Sales & Marketing
Mr. Ara Aprahamian
VP & Head of Human Resource
Ms. Michele Visosky
Head of Procurement
Mr. Jayesh Shah
Show Less

See Also

Discover More
What is the Intrinsic Value of one TARO stock?

The intrinsic value of one TARO stock under the Base Case scenario is 28.2 USD.

Is TARO stock undervalued or overvalued?

Compared to the current market price of 42.26 USD, Taro Pharmaceutical Industries Ltd is Overvalued by 33%.